Clinical trial
Dasatinib in Treating Patients With Early Chronic Phase Chronic Myelogenous…
NCT00254423 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00254423 |
|---|---|
| Title | Dasatinib in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia |
| Official title | Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Dasatinib (BMS-354825) |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia |
| Intervention type | Drug |
| Interventions | Dasatinib |
| Enrollment | 150 |
| Start date | Nov 8, 2005 |
| Primary completion | Mar 14, 2025 |
| Completion | Mar 14, 2025 |
| First posted | Nov 16, 2005 |
| Last update posted | Jan 15, 2026 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: